Individual Patient Expanded Access Gilteritinib (ASP2215)
NCT03315299 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2024-02-07
Summary
The purpose of this study is to provide expanded access to ASP2215 for a single subject with refractory FLT3-mutated AML without access to comparable or alternative therapy.
Conditions
Interventions
- DRUG
-
ASP2215
Subject will take ASP2215 by mouth daily for 28 day cycles
Sponsors & Collaborators
-
Astellas Pharma Global Development, Inc.
collaborator INDUSTRY -
Etan Orgel
lead OTHER
Eligibility
- Min Age
- 12 Years
- Max Age
- 15 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
NCT02997202 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
NCT02310321 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
NCT03182244 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
NCT02421939 ·Status: COMPLETED ·Phase: PHASE3
-
Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant
NCT06734585 ·Status: COMPLETED
-
Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
NCT06696183 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
NCT05520567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT02236013 ·Status: COMPLETED ·Phase: PHASE1
-
Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML
NCT07259707 ·Status: RECRUITING ·Phase: PHASE2
-
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
NCT03836209 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
NCT06235801 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
NCT06022003 ·Status: RECRUITING ·Phase: PHASE2
-
A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia
NCT03451084 ·Status: COMPLETED ·Phase: PHASE2
-
flt3L in Treating Patients With Acute Myeloid Leukemia
NCT00006223 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation
NCT06561880 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review
NCT03047083 ·Status: COMPLETED
-
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
NCT04079296 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
NCT05756777 ·Status: RECRUITING ·Phase: PHASE1
-
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT05010122 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
NCT02864290 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
NCT04358393 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS
NCT01617226 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
NCT04027309 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
NCT00313586 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
NCT06045910 ·Status: RECRUITING ·Phase: PHASE1/PHASE2